[]

Find Clinical Drug Pipeline Developments & Deals for UNII-38R1Q0L1ZE

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Gabrail Cancer Center Research

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Gabrail Cancer Center Research

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Lead Product(s) : UNII-38R1Q0L1ZE

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Telix Pharmaceuticals | National Cancer Institute | National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 04, 2018

                          Lead Product(s) : UNII-38R1Q0L1ZE

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Telix Pharmaceuticals | National Cancer Institute | National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Bital Savir-Baruch

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Bital Savir-Baruch

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 21, 2017

                          Lead Product(s) : UNII-38R1Q0L1ZE

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Blue Earth Diagnostics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          GE Healthcare

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          GE Healthcare

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2010

                          Lead Product(s) : UNII-38R1Q0L1ZE

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank